prostaglandin synthase Inhibitors
1 drugsAbout prostaglandin synthase
Prostaglandin synthase, also known as cyclooxygenase (COX), is an enzyme involved in the production of prostaglandins, signaling molecules mediating inflammation, pain, and fever. It catalyzes the conversion of arachidonic acid to prostaglandins, playing a key role in the inflammatory response.
Prostaglandin synthase has long been a target for drug development, particularly for pain management and inflammation. Currently, there is no genetic evidence data available linking prostaglandin synthase to specific diseases.
Prostaglandin synthase is targeted by one FDA-approved drug, ibuprofen lysine, a small molecule approved in 2016. XGEN PHARMS is the only company with an approved drug targeting this enzyme, indicated for other conditions.
Top prostaglandin synthase Drugs
XGEN PHARMS is the only company with an approved drug targeting prostaglandin synthase.
Low competition suggests an opportunity for new entrants, but also a higher risk of market failure.
prostaglandin synthase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets prostaglandin synthase, using small molecule modality.
Explore alternative modalities like antibodies or biologics to differentiate from existing small molecule drugs.
prostaglandin synthase Clinical Trials 196 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on prostaglandin synthase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 35 | 29 | 5 | 1 | 85% |
| Phase 2 | 48 | 36 | 7 | 5 | 84% |
| Phase 3 | 46 | 33 | 10 | 3 | 77% |
| Phase 4 | 67 | 47 | 10 | 10 | 82% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
prostaglandin synthase Drug Approval Timeline (2016 - 2016)
The first and only drug, ibuprofen lysine, was approved in 2016.
Recent approval suggests renewed interest, but limited activity may indicate market saturation or challenges.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 151 (30 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on prostaglandin synthase. A trial counts if an approved drug acting on prostaglandin synthase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.